🔥 3 Must-Buy Stocks Right Now—Top Analysts’ Picks for September 10, 2025

Markets are roaring—and these picks lead the charge.

Wall Street’s sharpest minds just dropped their hottest recommendations. We’re talking equities with momentum, fundamentals, and enough upside to make traditional portfolio managers sweat.

🚀 High-Conviction Plays

Forget playing safe. These three names show brutal strength in a shaky macro climate—each flashing bullish signals even your cynical uncle would respect.

💸 One Ticker Dominating AI Infrastructure

It’s not NVDA. It’s not MSFT. It’s the quiet titan raking in contracts while Big Tech overspends on compute.

📈 The Energy Sleeper

Old-school sector, new-school margins. This pick’s leveraging regulatory chaos and global supply shocks to print cash. Boring? Profitable.

🛡️ The Defense Play Flying Under Radars

Geopolitical tension stays spicy. This stock’s backlog looks longer than a central banker’s excuse note.

Let’s be real—most “top analyst picks” are recycled consensus. But these three? Different breed. Different urgency. Different September.

Time to move.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

 (NVDA) – Nvidia is a semiconductor company known for its GPUs, widely used in gaming, data centers, and artificial intelligence. Yesterday, William Blair analyst Sebastien Naji maintained a Buy rating on the stock. Interestingly, 35 out of the 38 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 24.82%.

Syndax Pharmaceuticals (SNDX) – This is a clinical-stage biopharma company focused on developing cancer therapies. Today, Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on the stock with a price target of $44 per share. In the last three months, all five Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 162.08%.

ArriVent BioPharma (AVBP) – ArriVent BioPharma is a clinical-stage biopharma company developing targeted cancer therapies. Yesterday, Citi analyst Yigal Nochomovitz maintained a Buy rating on the stock with a price target of $23 per share. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 91.73%.

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.